CD8A and neoplasm: The proportion of tumor-infiltrating CD8+ T cells was highest in mice treated with ULNPs-cRNAIL-2F@G, with levels being 0.6-, 1.4-, 5.9-, and 40.9-fold higher than those in mice treated with CLNPs-cRNAIL-2F@G, ULNPs-cRNAIL-2F, CLNPs-cRNAIL-2F, and PBS, respectively (Fig. 7G).